靶向补体系统在ANCA相关血管炎管理中的应用
ANCA相关血管炎(AAV)患者死亡率高于一般人群,糖皮质激素(GC)治疗毒性风险高。3期ADVOCATE试验表明,avacopan阻断替代补体途径联合免疫抑制治疗,可在不损害疗效或安全性的情况下减少GC暴露;亚组分析显示对肾损害、肺部表现和AAV复发患者获益最大。
要点
- ADVOCATE试验显示avacopan联合免疫抑制可减少AAV患者GC暴露而不损害疗效或安全性。
- 亚组分析显示avacopan对肾损害、肺部表现和AAV复发患者获益最大。
- GC治疗与高毒性风险相关,快速多学科团队和早期GC治疗可改善AAV结局。
核心结论
- avacopan阻断替代补体途径联合免疫抑制治疗,可在不损害疗效或安全性的情况下减少AAV患者的GC暴露。
研究设计与样本
- 3期ADVOCATE试验,纳入AAV患者。
主要发现
- ADVOCATE试验表明avacopan联合免疫抑制可减少GC暴露而不损害疗效或安全性结局。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ANCA-associated vasculitis (AAV) is a group of chronic multisystem inflammatory disorders affecting multiple organs throughout the body. Despite advances in AAV therapies, patients with AAV continue to experience higher rates of mortality than the general population. AAV outcomes can be improved by providing patients with rapid access to multidisciplinary medical teams and early treatment with glucocorticoid- (GC-) based therapy. However, GCs are associated with a high risk of toxicity. The phase 3 ADVOCATE trial demonstrates that blocking the alternative complement pathways using avacopan alongside immunosuppression enables patients with AAV to reduce their GC exposure without compromising efficacy or safety outcomes. ADVOCATE subgroup analyses show benefits for avacopan in patients with a wide range of AAV-related manifestations, disease stages and ages, with the greatest benefits in patients with kidney impairment, lung manifestations and AAV relapse.
引用
- de Groot K. Targeting the complement system in ANCA-associated vasculitis management. Rheumatology (Oxford). 2026. PMID: 41159410. doi:10.1093/rheumatology/keaf539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。